CD8A and neoplasm: This is consistent with previous studies showing that TCF1 + CD8 + T cells produce differentiated TCF1- terminally exhausted T cells that respond to immunotherapy and with intra-tumor tumor-reactive T cells being predominately terminally exhausted T cells after anti-PD-1 treatment14,39,40.